RBC Capital Reiterates Outperform on Alnylam Pharmaceuticals, Maintains $55 Price Target
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza has reiterated an Outperform rating for Alnylam Pharmaceuticals (NASDAQ:AGIO) and maintained a price target of $55.
November 01, 2024 | 4:33 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital has reiterated its Outperform rating for Alnylam Pharmaceuticals, maintaining a price target of $55, indicating confidence in the company's future performance.
The reiteration of an Outperform rating and maintenance of a $55 price target by RBC Capital suggests positive sentiment and confidence in Alnylam Pharmaceuticals' future performance. This is likely to have a positive short-term impact on the stock price as it reflects analyst confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100